• 1. A new enantioselective synthesis of antiobesity drug lorcaserin
  Ganesh S. Ghotekar,Devidas A. More,Viswanadh Nalla,M. Muthukrishnan New J. Chem. 2019 43 16876
• 2. Design of oxa-spirocyclic PHOX ligands for the asymmetric synthesis of lorcaserin via iridium-catalyzed asymmetric hydrogenation
  Xiang-Yu Ye,Zhi-Qin Liang,Cong Jin,Qi-Wei Lang,Gen-Qiang Chen,Xumu Zhang Chem. Commun. 2021 57 195
• 3. Recent advancements in pharmacological strategies to modulate energy balance for combating obesity
  Benudhara Pati,Satyabrata Sendh,Bijayashree Sahu,Sunil Pani,Nivedita Jena,Naresh Chandra Bal RSC Med. Chem. 2023 14 1429
• 4. The toxicological assessment of two anti-obesity drugs in C. elegans
  Layla Aitlhadj,Stephen R. Stürzenbaum Toxicol. Res. 2013 2 145
• 5. Fabrication of liraglutide-encapsulated triple layer hyaluronic acid microneedles (TLMs) for the treatment of obesity
  Seorin Juhng,Jieun Song,Jeongyun You,Jihyun Park,Huisuk Yang,Mingyu Jang,Geonwoo Kang,Jiwoo Shin,Hyuk Wan Ko,Hyungil Jung Lab Chip 2023 23 2378

• Pharmaceutical and Biochemical Products Medical Disease Classifications

Lorcaserin (CAS No. 616202-92-7): A Comprehensive Overview of Its Mechanism, Applications, and Current Research Trends

Lorcaserin (CAS No. 616202-92-7) is a selective 5-HT2C receptor agonist that has garnered significant attention in the field of weight management and metabolic health. Marketed under the brand name Belviq, this compound was initially approved by the FDA in 2012 as an adjunct to diet and exercise for chronic weight management in adults with obesity or overweight conditions. The unique mechanism of Lorcaserin hydrochloride targets serotonin receptors in the brain, specifically the 5-HT2C receptor, which plays a pivotal role in regulating appetite and satiety.

In recent years, the demand for Lorcaserin weight loss solutions has surged, driven by the global obesity epidemic and increasing awareness of metabolic disorders. Searches for terms like "Lorcaserin side effects," "Lorcaserin vs. other weight loss drugs," and "Lorcaserin mechanism of action" reflect growing public interest. Unlike older appetite suppressants, Lorcaserin demonstrates high selectivity for the 5-HT2C receptor, minimizing off-target effects on other serotonin receptors (e.g., 5-HT2B, associated with cardiac valvulopathy). This specificity contributes to its favorable safety profile, though post-marketing studies continue to evaluate long-term outcomes.

The pharmacological properties of CAS 616202-92-7 have also sparked research beyond obesity. Studies explore its potential in treating conditions like type 2 diabetes, binge eating disorder, and even addiction, owing to serotonin's role in reward pathways. For instance, a 2023 meta-analysis highlighted Lorcaserin's efficacy in reducing HbA1c levels in diabetic patients, making it a dual-purpose therapeutic candidate. Such findings align with trending searches like "Lorcaserin and blood sugar control" or "new uses for Lorcaserin," indicating evolving consumer curiosity.

From a chemical perspective, Lorcaserin hydrochloride is synthesized as a white to off-white crystalline powder with a molecular formula of C₁₁H₁₄ClN·HCl. Its stability and solubility profile make it suitable for oral formulations, typically administered in 10 mg tablets. Analytical methods such as HPLC and mass spectrometry are employed to ensure purity, given the stringent regulatory standards for weight management drugs. Researchers frequently inquire about "Lorcaserin synthesis protocol" or "CAS 616202-92-7 suppliers," underscoring its relevance in pharmaceutical development.

Despite its benefits, Lorcaserin faced a setback in 2020 when the FDA requested its withdrawal due to a potential increased risk of cancer in rodent studies. This decision triggered debates about risk-benefit assessments, with some clinicians advocating for personalized approaches. Searches for "Lorcaserin FDA withdrawal reasons" or "is Lorcaserin banned" remain common, highlighting the need for transparent communication about drug safety.

Current trends emphasize precision medicine applications for Lorcaserin, including genetic testing to identify responders. Polymorphisms in the HTR2C gene may influence efficacy, a topic gaining traction in forums and scientific literature. Meanwhile, comparative analyses with newer agents like semaglutide dominate discussions, as patients seek "best weight loss drug 2024" options. Such dynamics illustrate how CAS No. 616202-92-7 continues to shape the obesity therapeutics landscape.

In conclusion, Lorcaserin (CAS No. 616202-92-7) represents a milestone in targeted pharmacotherapy for weight management. Its journey from approval to market withdrawal offers valuable insights into drug development challenges. As research uncovers novel applications and refinements in patient stratification, this compound remains a reference point for innovation in metabolic health—addressing both historical queries and emerging questions in the field.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)